These mediators activate key signaling pathways, including nuclear factor-kappa B (NF-κB) and the NLRP3 (nucleotide-binding domain, leucine-rich–containing family, pyrin domain-containing-3) inflammasome, which drive CRC progression by enhancing tumor microenvironment (TME) inflammation and immune dysregulation [13,14]. Here, NFKB1 is linked to neoplasm.